Tislelizumab trumps docetaxel in pre-treated NSCLC
13 Thg5 2021
The anti-PD-1 antibody tislelizumab may help improve patient outcomes vs docetaxel as second- or third-line treatment for advanced or metastatic non–small-cell lung cancer (NSCLC) regardless of histology or PD-L1 expression, interim findings from the phase III RATIONALE 303 study have shown.
Navigating the CPP patient journey – case-based discussion for nurses
06 Thg5 2021;
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.